276 related articles for article (PubMed ID: 26298811)
1. Computational discovery of novel HIV-1 entry inhibitors based on potent and broad neutralizing antibody VRC01.
Andrianov AM; Kashyn IA; Tuzikov AV
J Mol Graph Model; 2015 Sep; 61():262-71. PubMed ID: 26298811
[TBL] [Abstract][Full Text] [Related]
2. Discovery of novel anti-HIV-1 agents based on a broadly neutralizing antibody against the envelope gp120 V3 loop: a computational study.
Andrianov AM; Kashyn IA; Tuzikov AV
J Biomol Struct Dyn; 2014 Dec; 32(12):1993-2004. PubMed ID: 24251545
[TBL] [Abstract][Full Text] [Related]
3. In silico design of novel broad anti-HIV-1 agents based on glycosphingolipid β-galactosylceramide, a high-affinity receptor for the envelope gp120 V3 loop.
Andrianov AM; Kornoushenko YV; Kashyn IA; Kisel MA; Tuzikov AV
J Biomol Struct Dyn; 2015; 33(5):1051-66. PubMed ID: 24942968
[TBL] [Abstract][Full Text] [Related]
4. [Virtual screening of small molecular HIV-1 entry inhibitor NC-2 targeting gp120 and its action mechanism].
Duan H; Wang Y; Song D; Chen Z; Qiu J; Lu L; Jiang S; Liu S; Tan S
Nan Fang Yi Ke Da Xue Xue Bao; 2013 Jun; 33(6):826-31. PubMed ID: 23803191
[TBL] [Abstract][Full Text] [Related]
5. Structural mimicry of CD4 by a cross-reactive HIV-1 neutralizing antibody with CDR-H2 and H3 containing unique motifs.
Prabakaran P; Gan J; Wu YQ; Zhang MY; Dimitrov DS; Ji X
J Mol Biol; 2006 Mar; 357(1):82-99. PubMed ID: 16426633
[TBL] [Abstract][Full Text] [Related]
6. Structural basis for germline antibody recognition of HIV-1 immunogens.
Scharf L; West AP; Sievers SA; Chen C; Jiang S; Gao H; Gray MD; McGuire AT; Scheid JF; Nussenzweig MC; Stamatatos L; Bjorkman PJ
Elife; 2016 Mar; 5():. PubMed ID: 26997349
[TBL] [Abstract][Full Text] [Related]
7. Peptide Triazole Inactivators of HIV-1 Utilize a Conserved Two-Cavity Binding Site at the Junction of the Inner and Outer Domains of Env gp120.
Aneja R; Rashad AA; Li H; Kalyana Sundaram RV; Duffy C; Bailey LD; Chaiken I
J Med Chem; 2015 May; 58(9):3843-58. PubMed ID: 25860784
[TBL] [Abstract][Full Text] [Related]
8. Selection of peptide mimics of HIV-1 epitope recognized by neutralizing antibody VRC01.
Chikaev AN; Bakulina AY; Burdick RC; Karpenko LI; Pathak VK; Ilyichev AA
PLoS One; 2015; 10(3):e0120847. PubMed ID: 25785734
[TBL] [Abstract][Full Text] [Related]
9. How can (-)-epigallocatechin gallate from green tea prevent HIV-1 infection? Mechanistic insights from computational modeling and the implication for rational design of anti-HIV-1 entry inhibitors.
Hamza A; Zhan CG
J Phys Chem B; 2006 Feb; 110(6):2910-7. PubMed ID: 16471901
[TBL] [Abstract][Full Text] [Related]
10. Understanding the molecular mechanism of the broad and potent neutralization of HIV-1 by antibody VRC01 from the perspective of molecular dynamics simulation and binding free energy calculations.
Zhang Y; Pan D; Shen Y; Jin N; Liu H; Yao X
J Mol Model; 2012 Sep; 18(9):4517-27. PubMed ID: 22643972
[TBL] [Abstract][Full Text] [Related]
11. Computational studies identifying entry inhibitor scaffolds targeting the Phe43 cavity of HIV-1 gp120.
Tintori C; Selvaraj M; Badia R; Clotet B; Esté JA; Botta M
ChemMedChem; 2013 Mar; 8(3):475-83. PubMed ID: 23404750
[TBL] [Abstract][Full Text] [Related]
12. In Silico Identification of Novel Aromatic Compounds as Potential HIV-1 Entry Inhibitors Mimicking Cellular Receptor CD4.
Andrianov AM; Nikolaev GI; Kornoushenko YV; Xu W; Jiang S; Tuzikov AV
Viruses; 2019 Aug; 11(8):. PubMed ID: 31412617
[TBL] [Abstract][Full Text] [Related]
13. A 2-4-Amino Acid Deletion in the V5 Region of HIV-1 Env gp120 Confers Viral Resistance to the Broadly Neutralizing Human Monoclonal Antibody, VRC01.
Tachibana S; Sasaki M; Tanaka T; Inoue M; Ophinni Y; Kotaki T; Kameoka M
AIDS Res Hum Retroviruses; 2017 Dec; 33(12):1248-1257. PubMed ID: 28903577
[TBL] [Abstract][Full Text] [Related]
14. Computational model of the HIV-1 subtype A V3 loop: study on the conformational mobility for structure-based anti-AIDS drug design.
Andrianov AM; Anishchenko IV
J Biomol Struct Dyn; 2009 Oct; 27(2):179-93. PubMed ID: 19583444
[TBL] [Abstract][Full Text] [Related]
15. Molecular docking guided structure based design of symmetrical N,N'-disubstituted urea/thiourea as HIV-1 gp120-CD4 binding inhibitors.
Sivan SK; Vangala R; Manga V
Bioorg Med Chem; 2013 Aug; 21(15):4591-9. PubMed ID: 23777826
[TBL] [Abstract][Full Text] [Related]
16. Potential HIV-1 fusion inhibitors mimicking gp41-specific broadly neutralizing antibody 10E8: In silico discovery and prediction of antiviral potency.
Andrianov AM; Kashyn IA; Tuzikov AV
J Bioinform Comput Biol; 2018 Apr; 16(2):1840007. PubMed ID: 29439644
[TBL] [Abstract][Full Text] [Related]
17. A broad spectrum anti-HIV inhibitor significantly disturbs V1/V2 domain rearrangements of HIV-1 gp120 and inhibits virus entry.
Berinyuy E; Soliman ME
J Recept Signal Transduct Res; 2016; 36(2):119-29. PubMed ID: 26446906
[TBL] [Abstract][Full Text] [Related]
18. Identification of Novel Potential gp120 of HIV-1 Antagonist Using Per-Residue Energy Contribution-Based Pharmacophore modelling.
Berinyuy E; Soliman MES
Interdiscip Sci; 2017 Sep; 9(3):406-418. PubMed ID: 27165479
[TBL] [Abstract][Full Text] [Related]
19. Application of deep learning and molecular modeling to identify small drug-like compounds as potential HIV-1 entry inhibitors.
Andrianov AM; Nikolaev GI; Shuldov NA; Bosko IP; Anischenko AI; Tuzikov AV
J Biomol Struct Dyn; 2022 Oct; 40(16):7555-7573. PubMed ID: 33855929
[TBL] [Abstract][Full Text] [Related]
20. Structural basis for HIV-1 gp120 recognition by a germ-line version of a broadly neutralizing antibody.
Scharf L; West AP; Gao H; Lee T; Scheid JF; Nussenzweig MC; Bjorkman PJ; Diskin R
Proc Natl Acad Sci U S A; 2013 Apr; 110(15):6049-54. PubMed ID: 23524883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
